Table 1.

Select baseline characteristics (intention-to-treat population)

CharacteristicCohort 1prior platinum therapy (n = 49)Cohort 2 third-line treatment, no. prior platinum therapy (n = 35)Total (N = 84)
Age, median (range), years50 (31–74)52 (33–75)50 (31–75)
ECOG performance status = 0, n (%)34 (69)15 (43)49 (58)
History of central nervous system metastasis, n (%)8 (16)1 (3)9 (11)
Visceral disease, n (%)38 (78)23 (66)61 (73)
Hormone receptor status, n (%)
 HER2-positive1 (2)5 (14)6 (7)
 Triple-negative29 (59)6 (17)35 (42)
 ER-positive or PgR-positive20 (41)29 (83)49 (58)
BRCA mutation status, n (%)
BRCA1-positive26 (53)15 (43)41 (49)
BRCA2-positive22 (45)20 (57)42 (50)
 Unknown1 (2)01 (1)
Number of prior cytotoxic regimens for advanced disease
 1 to 2, n (%)26 (53)1 (3)a27 (32)
 3 to 4, n (%)17 (35)22 (63)39 (46)
 ≥5, n (%)6 (12)12 (34)18 (21)
 Median243
 Min, max1, 101, 91, 10
  • Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.

  • aProtocol deviation: eligibility criteria not met (≥3 prior cytotoxic regimens).